Identification
Instrument name
INVENTIVA
Symbol
IVA
ISIN code
FR0013233012
Exchange / Market
Euronext
Trading location
Paris
Products family
Stocks
Capitalization compartment
Compartment B
ICB
Biotechnology
Operation
IPO date
IPO price
EUR 8.50
Issue type
Initial Public offering
Catégorie
IPO
Price range
EUR 8.50 - EUR 9.75

Company profile

Inventiva S.A. is a biopharmaceutical company specialized in the treatment of diseases in the fields of fibrosis, lysosomal overload and oncology. The group is developing two drug candidates - lanifibranor and odiparcil - in non-alcoholic steatohepatitis (« NASH ») and mucopolysaccharidosis (« MPS ») respectively, as well as a portfolio of several programs in the preclinical stage. Lanifibranor is currently in Phase IIb for the treatment of patients with NASH and Odiparcil is currently in Phase IIa for the treatment of type VI MPS. Meanwhile, Inventiva is in the process of selecting an oncology drug candidate for the Hippo signaling pathway. Two collaborations are in place with AbbVie, which is currently evaluating ABBV-157 in Phase I. This partnership provides for milestone payments to Inventiva as well as royalties on product sales. Partnership with Boehringer Ingelheim ended on September 30, 2019.

Source: Cofisem - Last Update: 17 Jul 2020
Key Executives
Chairman and Chief Executive Officer Frédéric Cren
Deputy CEO Pierre Broqua
Administrative & Finance Director Jean Volatier
Source: Cofisem - Last Update: 18 Jun 2020
Key figures
Millenium 2019 2018 2017 2016 2015
Net sales 6,998 3,197 6,521 9,446 4,875
Income from ordinary activities 6,998 3,197 6,521 14,352 8,663
Operating income -30,312 -33,253 -20,916 -13,019 -15,510
Cost (net) of financial indebtedness 154 -86 269 221
Equity-accounted companies' contribution to results
Net profit from discontinued activities
Net income -30,218 -33,617 -17,229 -7,045 -8,823
Net income (Group share) -30,218 -33,617 -17,229 -7,045 -8,823
Fiscal year end 12.19 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 17 Jul 2020
Shareholder information
BVF Partners LP 20.73 %
Cren 18.59 %
New Entreprise Associates 17 L.P 13.39 %
Pierre Broqua 12.65 %
Novo A/S 8.70 %
Sofinnova 7.00 %
Employees 1.60 %
Group-owned stock 0.30 %
Source: Cofisem - Last Update: 17 Jul 2020